Is there any difference between the obstetric and perinatal complications of pregnancy in patients with and without repeated implantation failure in fresh and frozen-thawed embryo transfer cycles?

Middle East Fertility Society Journal

Table 1 Maternal characteristic of the patients in the control and RIF groups of the fresh ET cycles (n=216)

Variables	Control (n=191)	RIF (n=25)	P-value
Age (yr.)^a	31.00 (7.00)	34.50 (2.50)	0.09
AMH (ng/ml)^a	2.97 (2.93)	3.95 (4.00)	0.93
Cycle day^a	15.00 (3.00)	14.00 (4.50)	0.61
Gonadotropin dose (IU)^a	1725.00 (1068.75)	1875.00 (712.50)	0.92
Duration of infertility (yr.)^a	6.00 (6.00)	7.50 (6.50)	0.27
Protocols
Agonist	30 (15.7)	3 (12)	0.57
Antagonist	117 (61.3)	18 (72)
Micro dose	44 (23)	4 (16)
Trigger
HCG	138 (72.3)	15 (60)	0.42
Agonist	24 (12.6)	5 (20)
Double	29 (15.2)	5 (20)
Number of ET
1	22 (11.5)	5 (20)	0.23
2	145 (75.9)	15 (60)
3	24 (12.6)	5 (20)
Indications for IVF treatment
Male factor	87 (45.5)	8 (32)	0.33
Female factor	46 (24.1)	6 (24)
Unexplained factor	5 (2.6)	2 (8)
Male and female factors	53 (27.7)	9 (36)
Type of infertility			0.54
Primary	161 (84.3)	23 (92)
Secondary	30 (15.7)	2 (8)

^aNon-parametric data were presented with median (interquartile range). The numerical data were presented with frequency (percent). P < 0.05 was considered as significant. AMH anti-Mullerian hormone, ET embryo transfer